Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Michetti

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Scandinavian Journal of Gastroenterology|July 27, 2010
Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohortPascal Juillerat, Valérie Pittet, Christian Mottet, et al.
Journal of Crohn'S & Colitis|December 22, 2010
Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT IIPierre Michetti, Marc Stelle, Pascal Juillerat, et al.
Digestion|May 10, 2021
Risk of Vaccine-Preventable Infections in Swiss Adults with Inflammatory Bowel DiseaseLaure F Pittet, Charlotte M Verolet, Pierre Michetti, et al.
Inflammatory Bowel Diseases|December 17, 2009
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS surveyAlain M Schoepfer, Stephan R Vavricka, Janek Binek, et al.
European Journal of Gastroenterology & Hepatology|October 23, 2010
Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriatenessPascal Juillerat, Valérie Pittet, John-Paul Vader, et al.
Inflammatory Bowel Diseases|April 22, 2011
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel diseaseStephan R Vavricka, Sabrina M Spigaglia, Gerhard Rogler, et al.
Journal of Crohn'S & Colitis|June 28, 2020
Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should knowPhilipp Schreiner, Nicolas J Mueller, Jan Fehr, et al.
Digestive Diseases (Basel, Switzerland)|June 9, 2017
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III SurveyStephan R Vavricka, Milos Spasojevic, Gerhard Rogler, et al.
Inflammatory Bowel Diseases|June 16, 2011
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II surveyStephan R Vavricka, Alain M Schoepfer, Georg Bansky, et al.
European Journal of Gastroenterology & Hepatology|February 1, 2018
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease CohortSébastien Godat, Nicolas Fournier, Ekaterina Safroneeva, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Scandinavian Journal of Gastroenterology|July 27, 2010
Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohortPascal Juillerat, Valérie Pittet, Christian Mottet, et al.
Journal of Crohn'S & Colitis|December 22, 2010
Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT IIPierre Michetti, Marc Stelle, Pascal Juillerat, et al.
Digestion|May 10, 2021
Risk of Vaccine-Preventable Infections in Swiss Adults with Inflammatory Bowel DiseaseLaure F Pittet, Charlotte M Verolet, Pierre Michetti, et al.
Inflammatory Bowel Diseases|December 17, 2009
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS surveyAlain M Schoepfer, Stephan R Vavricka, Janek Binek, et al.
European Journal of Gastroenterology & Hepatology|October 23, 2010
Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriatenessPascal Juillerat, Valérie Pittet, John-Paul Vader, et al.
Inflammatory Bowel Diseases|April 22, 2011
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel diseaseStephan R Vavricka, Sabrina M Spigaglia, Gerhard Rogler, et al.
Journal of Crohn'S & Colitis|June 28, 2020
Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should knowPhilipp Schreiner, Nicolas J Mueller, Jan Fehr, et al.
Digestive Diseases (Basel, Switzerland)|June 9, 2017
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III SurveyStephan R Vavricka, Milos Spasojevic, Gerhard Rogler, et al.
Inflammatory Bowel Diseases|June 16, 2011
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II surveyStephan R Vavricka, Alain M Schoepfer, Georg Bansky, et al.
European Journal of Gastroenterology & Hepatology|February 1, 2018
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease CohortSébastien Godat, Nicolas Fournier, Ekaterina Safroneeva, et al.
Pageof 15